Navigation Links
BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 11th Annual Healthcare Conference
Date:9/3/2009

LYNBROOK, N.Y., Sept. 3 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009, at 12:05pm ET at the New York Palace Hotel in New York, NY.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link: http://www.wsw.com/webcast/rrshq15/bstc.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX(TM) product in Europe.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
3. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
4. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
5. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
6. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
7. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
8. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
9. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
10. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
11. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... /PRNewswire/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ... active lead drug candidate, PBI-4050, has been issued a ... and Healthcare Products Regulatory Agency ("MHRA") for the treatment ... designation is an early indication that a medicinal product ... Medicines Scheme ("EAMS"), intended for the treatment, diagnosis or ...
(Date:1/24/2017)... ... January 23, 2017 , ... Edward ... first-ever recipient of the National Academy of Sciences Prize in Food and Agriculture ... nutrition. , The annual National Academy of Sciences (NAS) Prize in Food and ...
(Date:1/24/2017)... , Jan. 23, 2017  Recognizing the ... on scientific discovery and solutions, the University of ... Frost Institutes for Science and Engineering to achieve ... mathematics (STEM) to help solve some of the ... Miami President Julio Frenk unveiled the ...
(Date:1/24/2017)... 2017   Instrument Business Outlook ( ... MN ) the 2016 Company of the ... newsletter tracking developments in the analytical and life ... consistently achieved outstanding technical, operational and financial results ... of IBO. "In 2016, Bio-Techne capitalized on opportunities ...
Breaking Biology Technology:
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
(Date:12/16/2016)... 16, 2016 Research and Markets has announced ... Global Forecast to 2021" report to their offering. ... The biometric vehicle access ... a CAGR of 14.06% from 2016 to 2021. The market is ... to reach 854.8 Million by 2021. The growth of the biometric ...
(Date:12/15/2016)... --  WaferGen Bio-systems, Inc. (NASDAQ: WGBS ... that on December 13, 2016, it received a letter ... Market LLC which acknowledged that, as of December 12, ... had been at $1.00 or greater for ten consecutive ... Rule 5550(a)(2) of the Nasdaq Stock Market. ...
Breaking Biology News(10 mins):